| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CA5A |
| Uniprot No | P35218 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 39-305aa |
| 氨基酸序列 | CAWQTSNNTLHPLWTVPVSVPGGTRQSPINIQWRDSVYDPQLKPLRVSYEAASCLYIWNTGYLFQVEFDDATEASGISGGPLENHYRLKQFHFHWGAVNEGGSEHTVDGHAYPAELHLVHWNSVKYQNYKEAVVGENGLAVIGVFLKLGAHHQTLQRLVDILPEIKHKDARAAMRPFDPSTLLPTCWDYWTYAGSLTTPPLTESVTWIIQKEPVEVAPSQLSAFRTLLFSALGEEEKMMVNNYRPLQPLMNRKVWASFQATNEGTRS |
| 预测分子量 | 30.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CA5A(碳酸酐酶5A)重组蛋白的参考文献及其摘要概括：
---
1. **文献名称**: "Cloning, expression, and characterization of mitochondrial carbonic anhydrase VA (CA5A) in a bacterial system"
**作者**: Smith A, et al.
**摘要**: 研究报道了在大肠杆菌中成功克隆并表达重组人源CA5A蛋白，优化了表达条件并通过亲和层析纯化。酶活性分析表明重组CA5A具有显著的CO₂水合酶活性，并探讨了其pH依赖性。
---
2. **文献名称**: "Structural insights into recombinant human CA5A: implications for metabolic acidosis disorders"
**作者**: Lee J, et al.
**摘要**: 通过X射线晶体学解析了重组CA5A的三维结构，揭示了其线粒体定位相关的结构特征。实验验证了突变体对酶活性的影响，为CA5A缺失相关代谢性酸中毒的机制提供了分子基础。
---
3. **文献名称**: "Functional reconstitution of recombinant CA5A in a cell-free system for urea cycle analysis"
**作者**: Chen R, et al.
**摘要**: 在无细胞系统中重组表达CA5A蛋白，模拟其在尿素循环中的功能。研究表明CA5A与相邻酶类的协同作用可提升氨解毒效率，为肝病治疗提供体外模型参考。
---
注：上述文献信息为模拟示例，实际文献需通过学术数据库(如PubMed、Web of Science)检索确认。
**Background of CA5A Recombinant Protein**
Carbonic anhydrase 5A (CA5A), a member of the carbonic anhydrase (CA) enzyme family, plays a critical role in catalyzing the reversible hydration of carbon dioxide (CO₂) to bicarbonate (HCO₃⁻) and protons (H⁺). This zinc metalloenzyme is primarily localized in mitochondria and is involved in maintaining cellular pH homeostasis, ion transport, and metabolic processes. CA5A is expressed in various tissues, including the liver, kidney, and brain, where it supports energy metabolism by regulating bicarbonate-dependent pathways, such as gluconeogenesis and ureagenesis.
Recombinant CA5A protein is engineered through genetic cloning and expression systems (e.g., *E. coli* or mammalian cell lines) to produce purified, biologically active CA5A for research and therapeutic applications. Its recombinant form retains the enzymatic activity of native CA5A, enabling studies on mitochondrial dysfunction, metabolic disorders, and diseases linked to CA dysregulation, such as certain cancers or inherited CA deficiencies.
Research on CA5A has gained momentum due to its potential as a biomarker or therapeutic target. For instance, altered CA5A expression has been associated with hepatocellular carcinoma and metabolic syndromes. Recombinant CA5A also serves as a tool for high-throughput drug screening to identify inhibitors or activators that modulate its activity, aiding in the development of novel therapies.
Overall, CA5A recombinant protein bridges fundamental biochemical research with translational applications, offering insights into cellular metabolism and opportunities for addressing CA-related pathologies. Its production and characterization continue to support advancements in enzymology, molecular biology, and precision medicine.
×
